Protagenic Therapeutics Inc New's Cash & cash equivalent grew by % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Protagenic Therapeutics Inc New's Quick Ratio to 0.07, Quick Ratio remained below Protagenic Therapeutics Inc new average.

Within Major Pharmaceutical Preparations industry 492 other companies have achieved higher Quick Ratio than Protagenic Therapeutics Inc New in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3702 to 3747.

Explain Quick Ratio?
How much Cash & cash equivalents PTIX�s has?
What are PTIX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PTIX Quick Ratio	(Sep 30 2026) Q2	(Jun 30 2026) Q1	(Mar 31 2026) Q4	(Dec 31 2025) Q3	(Sep 30 2025) Q2
Y / Y Current Liabilities Change	-88.11 %	-88.83 %	-4.23 %	623.78 %	1129.37 %
Y / Y Cash & cash equivalent Change	-97.18 %	-	10308.12 %	20.35 %	157.86 %
Quick Ratio MRQ	0.07	-	1.46	0.32	0.28
PTIX's Total Ranking	# 3747	# 3702	# 3305	# 5335	# 1757
Seq. Current Liabilities Change	7.52 %	3.99 %	-84.88 %	-29.68 %	1.02 %
Seq. Cash & cash equivalent Change	-	-	-31.79 %	-18.73 %	-33.54 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 493
Healthcare Sector	# 987
Overall Market	# 4798

Quick Ratio Statistics
High	Average	Low
20.76	3.84	0
(Dec 31 2021)		(Dec 31 2015)

Financial Statements
Protagenic Therapeutics Inc New's Current Liabilities	$ 1 Millions	Visit PTIX's Balance sheet
Protagenic Therapeutics Inc New's Cash & cash equivalent	$ 0 Millions	Visit PTIX's Balance sheet
Source of PTIX's Sales		Visit PTIX's Sales by Geography

Cumulative Protagenic Therapeutics Inc New's Quick Ratio

PTIX's Quick Ratio for the trailling 12 Months

PTIX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-52.73 %	50.08 %	679.74 %	853.78 %	731.42 %
Y / Y Cash & cash equivalent TTM Growth	-56.19 %	-8 %	174.97 %	44.9 %	2.5 %
Quick Ratio TTM	0.38	0.35	0.39	0.33	0.41
Total Ranking TTM	# 4696	# 0	# 2591	# 2955	#
Seq. Current Liabilities TTM Growth	-45.89 %	-31.41 %	-0.17 %	27.57 %	71.81 %
Seq. Cash & cash equivalent TTM Growth	-41.05 %	-38.86 %	16.52 %	4.31 %	23.79 %

Quick ratio ranking by company, industry and sector >> Back to PTIX Financial Strength Comparisons >> Go to Compare PTIX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Protagenic Therapeutics Inc New's average Cash & cash equivalent, this led to increase in in Protagenic Therapeutics Inc New's Quick Ratio to 0.38, Quick Ratio remained below PTIX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Quick Ratio than Protagenic Therapeutics Inc New. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 0 to 4696.

Explain Quick Ratio?
How much Cash & cash equivalents PTIX�s has?
What are PTIX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 489
Healthcare Sector	# 1003
Within the Market	# 4696

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.29	1.55	0.11
(Dec 31 2016)		(Dec 31 2015)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Igc Pharma Inc	0.13	$ 0.413 Millions	$ 3.143 Millions
Eli Lilly And Company	0.10	$ 4,885.000 Millions	$ 46,996.000 Millions
Protagenic Therapeutics Inc new	0.07	$ 0.077 Millions	$ 1.153 Millions

Date modified: 2026-11-07T06:41:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.